Research study into treatment for keratoconus and corneal ectasia
A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia.
A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia.
This research study will reveal whether there are any differences between the two riboflavin preparations during UV administration. The first preparation involves riboflavin in a dextran solution, which could keep the cornea thinner by removing water. In the second preparation riboflavin in a hypotonic solution will be used, which could keep the cornea more swollen.
The main goal of the study is to determine if the use of hypotonic riboflavin will help to maintain consistent corneal thickness during CXL. The secondary aim is to find out whether or not maintenance of the corneal thickness will benefit the reliability of the procedure, decrease corneal haze formation and improve safety of the endothelial cells.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
